Given the well-characterized GBM related immunosuppressive tumor microenvironment, treatment with PD-L1 inhibitors may present important weapons against this disease, such as targeting the DDR in GBM cells following radiation therapy (39, 40). This evidence concerns the gene CD274 and neoplasm.